What is Seer?
Founded in 2017 and based in Redwood City, California, Seer operates at the forefront of life sciences, specializing in the capture of deep molecular insights from the proteome. Their innovative approach aims to unlock new understandings of biological processes and diseases. The company's focus on proteomic analysis positions it as a key player in the burgeoning field of precision medicine and advanced diagnostics, leveraging cutting-edge technology to address complex biological challenges.
How much funding has Seer raised?
Seer has raised a total of $479.5M across 7 funding rounds:
Series A
$6M
Series B
$36M
Series C
$17.5M
Series D
$55M
Multiple Rounds
$365M
Series A (2017): $6M with participation from Maverick Ventures
Series B (2018): $36M led by Maverick Ventures and Invus
Series C (2019): $17.5M supported by Maverick Ventures, Wing Companies, Invus, and AJU IB INVESTMENT
Series D (2019): $55M featuring aMoon
Other Financing Round (2020): $55M backed by Maverick Ventures, Fidelity Investments Inc., T. Rowe Price Associates, HBM Healthcare Investments AG, Invus, and aMoon
Share Placement (2020): $135M with participation from T. Rowe Price, SoftBank, Fidelity, and aMoon Fund
Stock Issuance/Offering (2020): $175M led by Undisclosed
Key Investors in Seer
Maverick Ventures
Maverick Ventures Israel is a venture capital firm dedicated to supporting technology start-ups by providing investment and operational support. They focus on diverse industries, seeking exceptional teams with differentiated technology and initial traction.
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
Wing Companies
Wing is a venture capital firm that invests in early-stage technology companies. They focus on sectors such as enterprise software, artificial intelligence, and fintech, aiming to partner with founders to build category-defining businesses.
What's next for Seer?
The substantial enterprise-level funding and recent strategic investment indicate Seer is poised for significant expansion and acceleration of its research and development initiatives. This capital infusion is expected to fuel further innovation in proteomic analysis, potentially leading to the development of new diagnostic tools and therapeutic strategies. Seer's trajectory suggests a strong focus on scaling its operations and solidifying its market position within the competitive life sciences sector, aiming to translate its molecular insights into tangible clinical applications.
See full Seer company page
